Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 44Pancreatic Neoplasms 37Carcinoma, Non-Small-Cell Lung 37Triple Negative Breast Neoplasms 28Ovarian Neoplasms 20Fallopian Tube Neoplasms 19Lung Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Neoplasm Metastasis 11Uterine Cervical Neoplasms 8Melanoma 7Inflammatory Breast Neoplasms 7Esophageal Squamous Cell Carcinoma 6Breast Neoplasms, Male 6Stomach Neoplasms 5Cholangiocarcinoma 5Brenner Tumor 5Pancreatic Adenocarcinoma 4Neoplasms 4Esophageal Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Urinary Bladder Neoplasms 3Pleural Effusion, Malignant 3Oropharyngeal Neoplasms 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Endometrial Neoplasms 3

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Mucinous Adenocarcinoma × Taxes × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡